Krackhardt, Florian http://orcid.org/0000-0001-5965-8817
Jörnten-Karlsson, Magnus
Waliszewski, Matthias
Knutsson, Mikael
Niklasson, Anna
Appel, Karl-Friedrich
Degenhardt, Ralf
Ghanem, Alexander
Köhler, Till
Ohlow, Marc-Alexander
Tschöpe, Carsten
Theres, Heinz
vom Dahl, Jürgen
Karlson, Björn W.
Maier, Lars S.
Funding for this research was provided by:
AstraZeneca
Charité - Universitätsmedizin Berlin
Article History
Accepted: 28 February 2022
First Online: 20 April 2022
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and is consistent with the International Council for Harmonisation and Good Clinical Practice, applicable regulatory requirements and the AstraZeneca policy on bioethics. It was approved by the responsible (local) ethics committees. This study was conducted in accordance with paragraph 23b <i>Medizinproduktegesetz</i> (German Medical Device Law). All necessary ethics votes were obtained by the participating centers prior to patient recruitment.
: All patients provided consent to participate online.
: All participating patients provided consent online.
: Florian Krackhardt received lecture fees from AstraZeneca; Magnus Jörnten-Karlsson, Anna Niklasson, Mikael Knutsson, and Björn W. Karlson were full‐time employees of AstraZeneca during the preparation of this manuscript. Carsten Tschöpe has received speaker fees and/or contributions to meetings from Abbott, Abiomed, AstraZeneca, Bayer, Berlin Chemie, Novartis, Pfizer, and Servier, all outside the submitted work. All other authors report no conflicts of interest.